Nuclear Medicine: Page 2

UM launches new research reactor with $10M deal

By AuntMinnie.com staff writers

The University of Missouri (UM) has inked a $10 million deal with a Korean consortium.

April 23, 2025

Shine Technologies, Modawina Medical sign UAE distribution deal

By AuntMinnie.com staff writers

Shine Technologies has signed an agreement with Modawina Medical Company to distribute Shine’s lutetium-177 isotope in the UAE.

April 22, 2025

Atom Nuclear Lab 400

Having a father with Alzheimer's could mean higher risk of the disease

By Kate Madden Yee

Having a father with Alzheimer's may be tied to a greater spread of the tau protein in the brain, researchers have reported.

April 9, 2025

China limits exports of rare earth elements, targets CT x-ray tubes

By Erik L. Ridley

China's Ministry of Commerce has announced export controls for several rare earth elements and launched investigations of imported CT x-ray tubes.

April 4, 2025

IAEA touts radionuclide development activities

The IAEA has highlighted its worldwide activities to meet increasing demands for alpha-emitting radionuclides for use in Targeted Alpha Therapy.

March 18, 2025

Ac-225: From nuclear waste to cancer treatment

U.S. Department of Energy (DOE) efforts to dispose of spent nuclear waste left over from the Cold War has turned into a boon for supplies of actinium-225 (Ac-225).

March 5, 2025

Kidneys appear to tolerate Lu-177 treatments

Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.

December 19, 2024

African American men respond more favorably to Ra-223 therapy

African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.

December 17, 2024

Prostate Imaging

Intraarterial PRRT safe in patients with meningioma

Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.

October 28, 2024

2024 10 28 Meningioma Thumbnail

NNSA's Mo-99 program: A bumpy ride

Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).

October 10, 2024

How effective is Pluvicto in a ‘real-world’ setting?

Pluvicto appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval.

September 20, 2024

SNMMI: PET-based protocol shows promise in radioligand therapy

By Amerigo Allegretto

A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.

June 12, 2024

Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.

Page 2 of 437